Indoco Remedies Share Price (INDOCO)
as on
| Source : NSE
Indoco Remedies Stock Performance
as on August 20, 2025 at 4:01 PM IST
Day's Low
Day's High
₹279.95₹291.4
1.11%
Downside
2.93%
Upside
52 Week's Low
52 Week's High
₹190₹387.5532.89%
Downside
36.90%
Upside
| Market Stats | |
| Previous Close | ₹291.35 |
| Open | ₹291.00 |
| Volume | 55.88K |
| Upper Circuit | ₹349.60 |
| Lower Circuit | ₹233.10 |
| Day's Low | ₹279.95 |
| Day's High | ₹291.4 |
| 52 Week Low | ₹190 |
| 52 Week High | ₹387.55 |
| Returns % | |
| 1 Month Return | -8.24 % |
| 3 Month Return | + 11.94 % |
| 1 Year Return | -13.22 % |
| 3 Year Return | -19.15 % |
| 5 Year Return | + 17.76 % |
Indoco Remedies Stock Fundamentals & Key Indicators
Check Indoco Remedies market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹2,687.64 Cr
Return on Equity (ROE)
10.83
PE Ratio (TTM)
-23.14
Return on capital employed (ROCE)
12.31
Industry PE ratio
43.53
Beta (LTM)
0.77
P/B Ratio
2.69
Dividend Yield
0.46
PEG Ratio
1.12
Quarterly Earnings Growth YOY
-2097.25
EPS (TTM)
10.52
Sector
Pharmaceuticals
Book Value
120.4
Technical Analysis
Bearish
View Technical Analysis
Indoco Remedies Stock's Interest Amongst Investors
Indoco Remedies Stock Valuation
Track how Indoco Remedies P/E has moved over time to understand its valuation trends.
Indoco Remedies in the last 5 years
Lowest (-705.32x)
April 24, 2019
Today (-23.14x)
August 19, 2025
Industry (43.53x)
August 19, 2025
Highest (242.71x)
September 6, 2018
Today’s Price to Earnings Ratio: -23.14x
Indoco Remedies Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Indoco Remedies.
based on 4 analysts
0.00%
Buy
50.00%
Hold
50.00%
Sell
50% of analysts recommend a 'SELL' rating for Indoco Remedies. Average target price of ₹260
Source: S&P Global Market Intelligence
Indoco Remedies Share Price Target
Get share price movements and forecasts by analysts on Indoco Remedies.
Indoco Remedies price forecast by 4 analysts
Downside of-10.76%
High
₹325
Target
₹260.00
Low
₹207
Indoco Remedies target price ₹260, a slight downside of -10.76% compared to current price of ₹283.1. According to 4 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Indoco Remedies revenue growth forecast
Expected growth rate Q1, FY2027:18.10%
Forecast
Actual
Including amortisation and stock based compensations
Indoco Remedies EPS growth forecast
EPS estimate Q1, FY2027:7.96%
Forecast
Actual
Source: S&P Global Market Intelligence
Indoco Remedies Ltd Financial Results
Get the annual and quarterly financial summary of Indoco Remedies Ltd, including revenue, profit, loss and more.
Indoco Remedies Earnings and Dividends
View detailed summary of the earnings and dividend history of Indoco Remedies.
Indoco Remedies Ltd Earnings Results
Indoco Remedies Ltd’s net profit fell -1466.03% since last year same period to ₹-35.79Cr in the Q1 2025-2026. On a quarterly growth basis, Indoco Remedies Ltd has generated 11.39% jump in its net profits since last 3-months.
Read More about Earnings ResultsIndoco Remedies Ltd Dividends May,2024
In the quarter ending March 2024, Indoco Remedies Ltd has declared dividend of ₹1.50 per share on 16 May 2024 - translating a dividend yield of 1.29%.
Read More about Dividends
Indices Featuring Indoco Remedies Stock
Check stock indices that include Indoco Remedies.
Indoco Remedies Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Indoco Remedies.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 58.9% | 0.00 | |
| Foreign Institutions | 1.22% | ||
| Mutual Funds | 18.55% | 0.16 | |
| Retail Investors | 20.83% | ||
| Others | 0.5% | 56.26 |
Indoco Remedies Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Indoco Remedies with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| 2,687.64 | 3.55% | 0.70 | 97 | 1,817 | ||
| BUY | 35,211.48 | 34.29% | 0.52 | 300 | 1,051 | |
| BUY | 17,215.55 | 11.42% | 0.71 | 836 | 7,234 | |
| NA | 4,772.09 | -3.88% | 1.88 | -343 | 71 | |
| BUY | 15,923.30 | 49.66% | 0.67 | 244 | 1,515 |
Indoco Remedies News & Key Events
Latest news and events in one place to help you make informed investing decisions in Indoco Remedies.
Indoco Remedies Secures USFDA Approval for Rivaroxaban - 13 Aug, 2025
Indoco Remedies received USFDA approval for Rivaroxaban tablets, a generic version of Xarelto, across multiple strengths. This approval positions Indoco to capitalize on the lucrative US anticoagulant market, boosting investor confidence.Indoco Remedies Faces Losses Despite EU GMP Certification - 24 Jul, 2025
Indoco Remedies received EU GMP certification for its Goa facility, boosting export potential. However, the company reported significant losses in Q1FY26, raising concerns about operational performance.
Insights on Indoco Remedies Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 18.52% to 18.55% in Jun 2025 quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, INDOCO stock has moved up by 25.8%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -40.39 Cr → -35.79 Cr (in ₹), with an average increase of 12.9% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 392.23 Cr → 439.52 Cr (in ₹), with an average increase of 10.8% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 139.2% return, outperforming this stock by 158.3%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 58.90% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 28.7% return, outperforming this stock by 41.9%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 21.02% to 20.83% in Jun 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 1.24% to 1.22% in Jun 2025 quarter
About Indoco Remedies Ltd
Revenue: ₹429.08Cr as on June 2025 (Q1 FY26)
Net Profit: ₹-36.35Cr as on June 2025 (Q1 FY26)
Listing date: 14 Jan, 2005
Chairperson Name: Suresh G Kare
| Organisation | Indoco Remedies Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| CEO | Suresh G Kare |
| E-voting on shares | Click here to vote |
Mutual Funds that own Indoco Remedies Stock
Check out the Mutual Funds with significant holdings in Indoco Remedies.
FAQs
What is Indoco Remedies share price today?
Indoco Remedies share price today stands at ₹283.1, Open: ₹291, Previous Close: ₹291.35, High: ₹291.4, Low: ₹279.95, 52 Week High: ₹387.55, 52 Week Low: ₹190 as on .
How to buy Indoco Remedies shares ?
To buy Indoco Remedies shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for INDOCO or Indoco Remedies Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Indoco Remedies shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Indoco Remedies?
Today's traded volume of Indoco Remedies is 55.88K. Which means that 55.88K shares of Indoco Remedies were bought and sold on the stock market during today's trading session.
What is Indoco Remedies's market cap today?
Today's market capitalisation of Indoco Remedies is ₹2,687.64 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Indoco Remedies?
Indoco Remedies’s 52 week high is ₹387.55 and 52 week low is ₹190. The current share price of Indoco Remedies is ₹283.1, which is -26.95% down from its 52 week high and 49.00% up from its 52 week low.